The next news will be on the quarterly CC. I wouldn't expect much there, because the ASCO abstracts will be released on May 15th and the news is embargoed until then. I expect CLDX to have a presence at ASCO with 011 and CDX-1127 (perhaps). The 2H13 will be filled with news on CDX-1135 and CDX-1127 and possibly something on the HIV vaccine. Hopefully, enrollment will start on a Phase III in breast cancer in the second half. A partnership on 011 would be great.